Modification and Labeling of AAV Vector Particles

Methods in Molecular Biology

Volumn 807, Issue , 2011, Pages 273-300

  Büning, Hildegard ^a   Bolyard, Chelsea M ^b,c   Hallek, Michael ^a   Bartlett, Jeffrey S ^b,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Capsid particles; Chemical modification; Labeling; Ligands; Mosaic

Indexed keywords

ADENO ASSOCIATED VIRUS; ARTICLE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE VECTOR; GENETICS; POLYMERASE CHAIN REACTION; VIRION; VIRUS CAPSID;

CAPSID; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; POLYMERASE CHAIN REACTION; VIRION;

EID: 83455195584     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-370-7_12     Document Type: Chapter

References (28)

1. Arnold, G. S., Sasser, A. K., Stachler, M. D., and Bartlett, J. S. (2006) Metabolic biotinyla-tion provides a unique platform for the purification and targeting of multiple AAV vector serotypes, Mol Ther 14, 97–106.
2. Nicklin, S. A., Buening, H., Dishart, K. L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A. J., Ali, R. R., Hallek, M., and Baker, A. H. (2001) Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells, Mol Ther 4, 174–181.
3. Shi, W., Arnold, G. S., and Bartlett, J. S. (2001) Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors, Hum Gene Ther 12, 1697–1711.
4. Perabo, L., Buning, H., Kofler, D. M., Ried, M. U., Girod, A., Wendtner, C. M., Enssle, J., and Hallek, M. (2003) In vitro selection of viral vectors with modified tropism: the adeno-associated virus display, Mol Ther 8, 151–157.
5. Shi, W., and Bartlett, J. S. (2003) RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism, Mol Ther 7, 515–525.
6. Hauck, B., Chen, L., and Xiao, W. (2003) Generation and characterization of chimeric recombinant AAV vectors, Mol Ther 7, 419–425.
7. Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., and Samulski, R. J. (2004) Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups, J Virol 78, 4421–4432.
8. Lux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., Kofler, D. M., Finke, S., Hallek, M., and Buning, H. (2005) Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking, J Virol 79, 11776–11787.
9. Warrington, K. H., Jr., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., and Muzyczka, N. (2004) Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus, J Virol 78, 6595–6609.
10. Keppler, A., Pick, H., Arrivoli, C., Vogel, H., and Johnsson, K. (2004) Labeling of fusion proteins with synthetic fluorophores in live
11. Stachler, M. D., Chen, I., Ting, A. Y., and Bartlett, J. S. (2008) Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase, Mol Ther 16, 1467–1473. cells, Proc Natl Acad Sci U S A 101, 9955–9959.
12. Miller, L. W., Sable, J., Goelet, P., Sheetz, M. P., and Cornish, V. W. (2004) Methotrexate conjugates: a molecular in vivo protein tag, Angew Chem Int Ed Engl 43, 1672–1675.
13. Bartlett, J. S., and Samulski, R. J. (1998) Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy, Nat Med 4, 635–637.
14. Bartlett, J. S., Wilcher, R., and Samulski, R. J. (2000) Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors, J Virol 74, 2777–2785.
15. Ren, C., White, A. F., and Ponnazhagan, S. (2007) Notch1 augments intracellular trafficking of adeno-associated virus type 2, J Virol 81, 2069–2073.
16. Sanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., and Engelhardt, J. F. (2000) Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation, J Virol 74, 9184–9196.
17. Seisenberger, G., Ried, M. U., Endress, T., Buning, H., Hallek, M., and Brauchle, C. (2001) Real-time single-molecule imaging of the infection pathway of an adeno-associated virus, Science 294, 1929–1932.
18. Bartlett, J. S., Samulski, R. J., and McCown, T. J. (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain, Hum Gene Ther 9, 1181–1186.
19. Li, J., Samulski, R. J., and Xiao, X. (1997) Role for highly regulated rep gene expression in adeno-associated virus vector production, J Virol 71, 5236–5243.
20. Xiao, X., Li, J., and Samulski, R. J. (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus, J Virol 72, 2224–2232.
21. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J. A. (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors, Hum Gene Ther 9, 2745–2760.
22. Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deleage, G., and Hallek, M. (1999) Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2, Nat Med 5, 1052–1056.
23. Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R. J. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J Virol 76, 791–801.
24. Wobus, C. E., Hugle-Dorr, B., Girod, A., Petersen, G., Hallek, M., and Kleinschmidt, J. A. (2000) Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection, J Virol 74, 9281–9293.
25. Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000) Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism, J Virol 74, 8635–8647.
26. Yang, Q., Mamounas, M., Yu, G., Kennedy, S., Leaker, B., Merson, J., Wong-Staal, F., Yu, M., and Barber, J. R. (1998) Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy, Hum Gene Ther 9, 1929–1937.
27. Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., and Weitzman, M. D. (2001) Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids, Mol Ther 3, 964–975.
28. Boucas, J., Lux, K., Huber, A., Schievenbusch, S., von Freyend, M. J., Perabo, L., Quadt-Humme, S., Odenthal, M., Hallek, M., and Buning, H. (2009) Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations, J Gene Med 11, 1103–1113.